Search Results

With Backing from Google, J&J and Others, BlackThorn Raises $76 Million Series B.

BlackThorn Therapeutics, Inc., a clinical-stage, neurobehavioral health company pioneering next-generation artificial intelligence (AI) technologies to advance targeted therapeutics, today announced the appointment of Monique Levy as chief strategy officer.

BlackThorn Therapeutics, Inc., announced that the company presented new data science research into the underlying biology of neurobehavioral disorders at the 49th annual meeting of the Society for Neuroscience taking place October 19-23 in Chicago.

BlackThorn Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing targeted medicines to treat central nervous system (CNS) disorders, today announced the advancement of Phase 2 clinical development for its lead drug candidate, BTRX-335140 (BTRX-140), a selective antagonist for the kappa opioid receptor (KOR)

Selective KOR Antagonist Represents BlackThorn’s Second Molecule to Enter Clinic

BlackThorn Therapeutics today announced the appointment of a key strategic executive to the company’s board of directors, George S. Golumbeski, Ph.D.

BTRX-335140 Poised to Enter Phase 2 Efficacy Studies and BTRX-323511 to Enter IND-enabling Studies

Focus on clinical tool development to advance new treatments for neurobehavioral disorders

Company Also Expands Board of Directors and Executive Management Team with Key Appointments